The present inventors succeeded in discovering specific amino acid mutationsin thevariable region, framework region, and constant region of TOCILIZUMAB, andthis enables toreduce immunogenicity risk and the heterogeneity originated from disulfidebonds in the hingeregion, as well as to improve antigen binding activity, pharmacokinetics,stability under acidicconditions, and stability in high concentration preparations.